Histamine-2 (H₂ ) antagonists can be safely removed from standard paclitaxel premedication regimens.

ABSTRACT:

Aims

The aim of this study is to investigate the rates of hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy, with and without a histamine-2 (H₂ ) antagonists.

Method

This prospective, multi-centre, cohort study compared patients receiving paclitaxel treated with premedication regimens containing chlorphenamine, dexamethasone and an H₂ antagonist vs patients treated without an H₂ antagonist. Rates of HSRs were described and logistic multivariable regression was used to investigate any associations with H₂ antagonist treatment, adjusting for confounding variables.

Results

A total of 1043 individuals were included in the study; of these, 638 (61%) patients received an H₂ antagonist and 405 (49%) were not given an H₂ antagonist. Incidence of HSR in the cohort treated with H₂ antagonists was 11.31% (n = 70) vs 9.86% (n = 41) in the cohort without. There was no statistically significant difference between the rates of HSR observed in those receiving and not receiving an H₂ antagonist (odds ratio 1.04, 95% CI 0.65, 1.66, P = .9).

Conclusions

Results presented within the study are consistent with other recently published evidence to suggest that H₂ antagonists do not confer any advantage as part of premedication regimens in reducing the incidence of HSR in patients treated with paclitaxel.

SUBMITTER: Foreman E 

PROVIDER: S-EPMC9545865 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature